Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex determining region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors. Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence. However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors. In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated that in BRAF V600E mutant cancers, BRAF inhibition can lead to rapid EGFR-mediated feedback activation [95,96,104].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Cited by
Items 101–200 of 916
Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing
Salton, M., Kasprzak, W. K., Voss, T. C., Shapiro, B. A., Poulikakos, P. I., & Misteli, T. (2015) · Nature Communications · doi:10.1038/ncomms8103 · Cited by 118
“Our results suggest that inhibition of splicing may be a complementary approach to currently used combination therapies of vemurafenib with MEK or HDAC inhibitors 14, 15, 31–33 .”
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
De Conti, G., Dias, M. H., & Bernards, R. (2021) · Cancers · doi:10.3390/cancers13051118 · Cited by 111
“This, in turn, leads to the restoration of vemurafenib sensitivity [7].”
BackgroundSelf-citationUnni, A. M., Harbourne, B., Oh, M. H., Wild, S. A., Ferrarone, J. R., Lockwood, W. W., & VARMUS, H. E. (2018) · eLife · doi:10.7554/elife.33718 · Cited by 123
Gerosa, L., Chidley, C., Fröhlich, F., Sanchez, G., Lim, S. K., Muhlich, J., Chen, J.-Y., Vallabhaneni, S., Baker, G. J., Schapiro, D., et al. (2020) · Cell Systems · doi:10.1016/j.cels.2020.10.002 · Cited by 110
“Despite elegant studies by Rosen and others (Lito et al., 2012; Sun et al., 2014), themechanisms of adaptiveMAPK reactivation in drug-treated BRAF melanoma cells remain unclear.”
BackgroundRole of cell surface proteoglycans in cancer immunotherapy
Espinoza‐Sánchez, N. A., & Götte, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.012 · Cited by 122
Zhang, L., Wang, Q., Wang, L., Xie, L., An, Y., Zhang, G., Zhu, W., Li, Y., Liu, Z., Zhang, X., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01262-3 · Cited by 110
“Mutant BRAF has been shown to be significantly associated with worsen overall survival and metastasis free survival of melanoma [8], meanwhile mutant BRAF has been also proven to be a good therapeutic target for melanoma, but the resistance of small molecule drugs against mutant BRAF for melanoma is invariably observe…”
BackgroundSelf-citation“RAF” neighborhood: Protein–protein interaction in the Raf/Mek/Erk pathway
Cseh, B., Doma, E., & Baccarini, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.025 · Cited by 105
“These cells, which acquire inhibitor resistance at the cost of their general fitness, are negatively selected during ‘‘drug holidays’’, restoring the sensitivity of the tumor population to the Raf inhibitor axis [114].”
BackgroundSandri, S., Faião‐Flores, F., Tiago, M., Pennacchi, P. C., Massaro, R. R., Alves-Fernandes, D. K., Berardinelli, G. N., Evangelista, A. F., Vazquez, V. D. L., Reis, R. M., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.017 · Cited by 115
“Also, EGFR activation could be associated with the slow growth phenotype of cells displaying hallmarks of oncogene-induced senescence [16] and conferred an advantage for BRAF melanoma cells [39], supporting the slow growth, higher doubling-time and lower colony number found in SKMEL-28 vemurafenib-resistant cells.”
BackgroundBai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107
Ahmad, S., Abu-Eid, R., Shrimali, R., Webb, M., Verma, V., Doroodchi, A., Berrong, Z., Samara, R., Rodriguez, P. C., Mkrtichyan, M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1839 · Cited by 107
“5nM)[18], GDC-0941 (PAN PI3K inhibitor) [19] were purchased from Selleckchem, (Houston, TX) The IC50 for each isoform is listed in (Supplementary Table 1).”
MethodTumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome
Venkatesan, S., & Swanton, C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158930 · Cited by 121
Wouters, J., Vizoso, M., Martínez‐Cardús, A., Carmona, F. J., Govaere, O., Laguna, T., Joseph, J., Dynoodt, P., Aura, C. M., Foth, M., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0851-3 · Cited by 109
BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape
Fedorenko, I. V., Wargo, J. A., Flaherty, K. T., Messina, J. L., & Smalley, K. S. M. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.329 · Cited by 105
“Recent reports have suggested that TGF-β released from melanoma cells upon BRAF inhibition may also increase RTK expression in melanoma cells (Sun et al., 2014).”
Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation
Braun, C. J., Bruno, P. M., Horlbeck, M. A., Gilbert, L. A., Weissman, J. S., & Hemann, M. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600582113 · Cited by 101
“This is particularly true for mechanisms leading to resistance to cancer treatment, where a gene transcript level may increase by gene amplification (16–20) or mere up-regulation (21, 22), which can lead to potent resistance phenotypes, ultimately resulting in treatment failure and patient death.”
BackgroundRathore, M. G., Girard, C. A. J., Ohanna, M., Tichet, M., Jouira, R. B., García, E., Larbret, F., Gesson, M., Audebert, S., Lacour, J. ‐., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0848-9 · Cited by 104
“Gene expression of PTX3 was also examined in data sets derived from patient tumor biopsies before and after development of drug resistance to Vemurafenib (GEO accession number GSE50535) [54].”
BackgroundOzkan-Dagliyan, I., Diehl, J. N., George, S. D., Schaefer, A., Papke, B., Klotz-Noack, K., Waters, A. M., Goodwin, C. M., Gautam, P., Pierobon, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107764 · Cited by 106
Chhouri, H., Alexandre, D., & Grumolato, L. (2023) · Cancers · doi:10.3390/cancers15020504 · Cited by 123
“Similar subpopulations of drug-tolerant cells have also been identified in other types of cancer, including colon cancer [76], melanoma [77], and glioblastoma [78].”
BackgroundRole of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies
Kim, M. H., & Kim, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2412-x · Cited by 110
Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma
Capparelli, C., Purwin, T. J., Glasheen, M. Q., Caksa, S., Tiago, M., Wilski, N. A., Pomante, D., Rosenbaum, S. R., Nguyen, M. Q., Cai, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28801-y · Cited by 110
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype
Wu, Y., Fletcher, M., Gu, Z., Wang, Q., Costa, B., Bertoni, A., Man, K.-H., Schlotter, M., Felsberg, J., Mangei, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20225-w · Cited by 101
Faião-Flores, F., Alves-Fernandes, D. K., Pennacchi, P. C., Sandri, S., Vicente, A. L. S. A., Scapulatempo-Neto, C., Vazquez, V. L., Reis, R. M., Chauhan, J., Goding, C. R., et al. (2017) · Oncogene · doi:10.1038/onc.2016.348 · Cited by 99
Zhang, S., Li, K., Dai, X., Chen, J., Chen, Z., Wang, M., Jiang, H., Wang, X., Bu, S., Liu, X., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.10.004 · Cited by 108
Kidger, A. M., Rushworth, L. K., Stellzig, J., Davidson, J., Bryant, C., Bayley, C., Caddye, E., Rogers, T., Keyse, S. M., & Caunt, C. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614684114 · Cited by 108
“Our results also support a growing body of evidence demonstrating that both normal and tumor cells are under strong selection pressure to maintain ERK activity within a narrow threshold range, such that both ERK inhibition and hyperactivation may cause tumor suppression (14, 15, 18, 41).”
ResultFallahi‐Sichani, M., Moerke, N. J., Niepel, M., Zhang, T., Gray, N. S., & Sorger, P. K. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145877 · Cited by 99
“Insensitivity to RAF inhibition in BRAFV600E melanomas frequently arises from adaptive responses that reactivate ERK (Lito et al, 2012) or up-regulate other pro-growth pathways such as the PI3K/AKT cascade (Shi et al, 2014a; Sun et al, 2014).”
Cancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma
Guan, J., Gupta, R., & Filipp, F. V. (2015) · Scientific Reports · doi:10.1038/srep07857 · Cited by 94
“We detected concurrent arm-level alteration of both arms of chromosomes 6, 20, 9, 10, 11 indicative of aneuploidy.”
HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
Faião‐Flores, F., Emmons, M. F., Durante, M. A., Kinose, F., Saha, B., Fang, B., Koomen, J. M., Chellappan, S., Maria–Engler, S. S., Rix, U., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3382 · Cited by 102
“Similar findings have been also reported in many other cancers including BRAF and NRAS-mutant melanoma; where BRAF and MEK inhibition frequently leads to a relief of feedback inhibition and increased signaling through multiple RTKs including IGF-1R, EGFR, ERBB3, EphA2 and c-MET (14, 40-43).”
ResultKorkut, A., Wang, W., Demir, E., Aksoy, B. A., Jing, X., Molinelli, E. J., Babur, Ö., Bemis, D. L., Onur Sumer, S., Solit, D. B., et al. (2015) · eLife · doi:10.7554/elife.04640 · Cited by 100
“Signaling pathways such as Wnt, RTK, TGFβ, and various others influence c-Myc stability, expression, and activity.”
BackgroundInfluentialHo, Y.-J., Anaparthy, N., Molik, D., Mathew, G., Aicher, T., Patel, A., Hicks, J., & Hammell, M. G. (2018) · Genome Research · doi:10.1101/gr.234062.117 · Cited by 97
“…in melanoma is widespread and presents a barrier to its efficacyas atherapeu-tic, because a large fraction of melanoma tumors initially respond to BRAF inhibition, but nearly all patients rapidly develop resistance (Müller et al. 2014; Shi et al. 2014; Sun et al. 2014; Perna et al. 2015).”
Noeparast, A., Teugels, E., Giron, P., Verschelden, G., De Brakeleer, S., Decoster, L., & De Grève, J. (2017) · Oncotarget · doi:10.18632/oncotarget.11635 · Cited by 98
“In melanoma patients harboring BRAF-V600 mutations, a combination of Dabrafenib with the allosteric MEK inhibitor Trametinib has been shown to improve overall survival and decrease the risk of adverse events related to paradoxical ERK activation when compared to Vemurafenib and Dabrafenib monotherapy, although ultimat…”
Rossi, A., Roberto, M., Panebianco, M., Botticelli, A., Mazzuca, F., & Marchetti, P. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172621 · Cited by 99
Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0768 · Cited by 94
Self-citationUnderstanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 98
“Such largescale screens can also be effectively tailored using smaller sets of genes; for example, a chromatin regulator-focused shRNA library [52].”
BackgroundClinical Evolution of Epithelial–Mesenchymal Transition in Human Carcinomas
Navas, T. A., Kinders, R. J., Lawrence, S. M., Ferry‐Galow, K. V., Borgel, S. D., Hollingshead, M. G., Srivastava, A. K., Alcoser, S. Y., Makhlouf, H. R., Chuaqui, R. F., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-18-3539 · Cited by 101
“The posttreatment return to the baseline epithelial–mesenchymal distribution is reminiscent of the resensitization to targeted and cytotoxic treatments observed in certain melanoma (59, 60) and triple-negative breast cancer (61) models after drug holidays.”
BackgroundValpione, S., Carlino, M. S., Mangana, J., Mooradian, M. J., McArthur, G. A., Schadendorf, D., Hauschild, A., Menzies, A. M., Arance, A. M., Ascierto, P. A., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.007 · Cited by 97
“Other models for transient acquired resistance include signalling plasticity [27,30,31], phenotype switching [32], quiescence [33,34] or epigenetic changes [35].”
BackgroundER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Ojha, R., Leli, N. M., Onorati, A., Piao, S., Verginadis, I. I., Tameire, F., Rebecca, V. W., Chude, C. I., Murugan, S., Fennelly, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0348 · Cited by 91
Leveraging Transcriptional Dynamics to Improve BRAF Inhibitor Responses in Melanoma
Smalley, I., Kim, E., Li, J., Spence, P., Wyatt, C. J., Eroglu, Z., Sondak, V. K., Messina, J. L., Babacan, N. A., Maria–Engler, S. S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.023 · Cited by 99
“At the single cell level, individual cells were identified that had high expression of MITF, Axl and cyclin D1 and increased expression of resistance conferring genes such as EGFR [2,39].”
BackgroundInfluentialThe ERK cascade inhibitors: Towards overcoming resistance
Maik-Rachline, G., & Seger, R. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.12.001 · Cited by 96
Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer
Chen, Y., & Zhang, Y. (2018) · Advanced Science · doi:10.1002/advs.201700964 · Cited by 100
Neuropilins in the Context of Tumor Vasculature
Niland, S., & Eble, J. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030639 · Cited by 98
“A de novo expression of NRP1 in BRAF-addicted melanoma cells contributes significantly to their development of secondary drug resistance by adapting their gene expression, such as upregulation of EGFR [200,259,260].”
BackgroundWebster, M. R., Xu, M., Kinzler, K. A., Kaur, A., Appleton, J., O'Connell, M. P., Marchbank, K., Valiga, A., Dang, V. M., Perego, M., et al. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12330 · Cited by 88
“Other work has also shown that where TGFb induces a senescent-like, slow-growing phenotype in melanoma, exposure of melanoma cells to TGFb in the presence of vemurafenib can subsequently promote proliferation, suggesting that the observed senescence is not terminal (Sun et al., 2014).”
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
Donnella, H. J., Webber, J. T., Levin, R. S., Camarda, R., Momcilovic, O., Bayani, N., Shah, K. N., Korkola, J. E., Shokat, K. M., Goga, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0081-9 · Cited by 90
Zhang, X., Niu, W., Mu, M., Hu, S., & Niu, C. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01695-8 · Cited by 102
Mechanisms of angiogenesis in tumour
Zhang, R., Yao, Y., Gao, H., & Hu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1359069 · Cited by 109
Network propagation in the cytoscape cyberinfrastructure
Carlin, D. E., Demchak, B., Pratt, D., Sage, E., & Ideker, T. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005598 · Cited by 86
Dual-target kinase drug design: Current strategies and future directions in cancer therapy
Sun, D., Zhao, Y., Zhang, S., Zhang, L., Liu, B., & Ouyang, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112025 · Cited by 84
Deep generative neural network for accurate drug response imputation
Jia, P., Hu, R., Pei, G., Dai, Y., Wang, Y., & Zhao, Z. (2021) · Nature Communications · doi:10.1038/s41467-021-21997-5 · Cited by 108
Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0193 · Cited by 88
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
TGF-β induces p53/Smads complex formation in the PAI-1 promoter to activate transcription
Kawarada, Y., Inoue, Y., Kawasaki, F., Fukuura, K., Sato, K., Tanaka, T., Itoh, Y., & Hayashi, H. (2016) · Scientific Reports · doi:10.1038/srep35483 · Cited by 89
Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming
Torrano, J., Emran, A. A., Hammerlindl, H., & Schaider, H. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0644-y · Cited by 95
MITF Modulates Therapeutic Resistance through EGFR Signaling
Ji, Z., Erin Chen, Y., Kumar, R., Taylor, M., Jenny Njauw, C.-N., Miao, B., Frederick, D. T., Wargo, J. A., Flaherty, K. T., Jönsson, G., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.105 · Cited by 86
“COT expression(Johannessen et al., 2010), SOX10 reduction(Sun et al., 2014), BRAF amplification(Shi et al., 2012), splice variation(Poulikakos et al., 2011), NRAS mutagenesis and receptor tyrosine kinase (RTK) activation(Girotti et al., 2013; Nazarian et al., 2010; Villanueva et al., 2010; Yadav et…”
BackgroundInfluentialMAPK kinase signalling dynamics regulate cell fate decisions and drug resistance
Rauch, N., Rukhlenko, O. S., Kölch, W., & Kholodenko, B. Ν. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.07.019 · Cited by 98
“In addition, other cellular processes, including TGFb signalling, chromatin modifying enzymes, and the Mediator complex, have recently been linked to drug resistance in high-throughput screens and could possibly lead to novel therapeutic strategies [53,54,55 ,56].”
BackgroundBRAF in malignant melanoma progression and metastasis: potentials and challenges.
Alqathama, A. A. (2020) · PubMed · Cited by 108
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
Fedorenko, I. V., Abel, E. V., Koomen, J. M., Fang, B., Wood, E. R., Chen, Y. A., Fisher, K. J., Iyengar, S., Dahlman, K. B., Wargo, J. A., et al. (2016) · Oncogene · doi:10.1038/onc.2015.188 · Cited by 85
Han, S., Ren, Y., He, W., Liu, H., Zhi, Z., Zhu, X., Yang, T., Rong, Y., Ma, B., Purwin, T. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02354-x · Cited by 83
Gupta, R., Malvi, P., Parajuli, K. R., Janoštiak, R., Bugide, S., Cai, G., Zhu, L. J., Green, M. R., & Wajapeyee, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005156117 · Cited by 96
“We inhibited each of these pathways by treating PDAC cells with the MEK inhibitor trametinib (26) or the PI3K inhibitor wortmannin (27) and then measured the mRNA and protein expression of KLF7.”
MethodSong, K., Minami, J. K., Huang, A. J. Y., Dehkordi, S. R., Lomeli, S. H., Luebeck, J., Goodman, M. H., Moriceau, G., Krijgsman, O., Dharanipragada, P., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0936 · Cited by 88
Jessen, C., Kreß, J. K. C., Baluapuri, A., Hufnagel, A., Schmitz, W., Kneitz, S., Roth, S., Marquardt, A., Appenzeller, S., Ade, C. P., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01477-8 · Cited by 89
Siu, M. K., Tsai, Y.-C., Chang, Y.-S., Yin, J., Suau, F., Chen, W.-Y., & Liu, Y.-N. (2014) · Oncogene · doi:10.1038/onc.2014.414 · Cited by 81
Kemper, K., Krijgsman, O., Kong, X., Cornelissen-Steijger, P., Shahrabi, A., Weeber, F., van der Velden, D. L., Bleijerveld, O. B., Kuilman, T., Kluin, R. J. C., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.064 · Cited by 82
“…resistancemecha- nisms in the post-vemurafenib PDX panel, including hyperactivation of c-MET (Ver- gani et al., 2011), EGFR overexpression (Sun et al., 2014), loss of PTEN (Paraiso et al., 2011) (Figure 5B), amplification of BRAFT1799A (Shi et al., 2014b) (Fig- ure 5C), and…”
Self-citationUnderstanding Drug Sensitivity and Tackling Resistance in Cancer
Tyner, J. W., Haderk, F., Kumaraswamy, A., Baughn, L. B., Van Ness, B., Liu, S., Marathe, H., Alumkal, J. J., Bivona, T. G., Chan, K. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3695 · Cited by 78
Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis
Hölzel, M., & Tüting, T. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.009 · Cited by 85
B-Raf Inhibition in the Clinic: Present and Future
Fiskus, W. C., & Mitsiades, N. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-090514-030732 · Cited by 85
Gómez-Miragaya, J., Palafox, M., Paré, L., Yoldi, G., Ferrer, I., Vila, S., Galván, P., Pellegrini, P., Pérez-Montoyo, H., Igea, A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.03.026 · Cited by 75
“This regain of sensitivity, the so-called ‘‘drug holiday,’’ has been described for targeted therapies in melanoma (Das Thakur et al., 2013; Sun et al., 2014).”
BackgroundNeuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies
Rizzolio, S., Cagnoni, G., Battistini, C., Bonelli, S., Isella, C., Ginderachter, J. A. V., Bernards, R., Nicolantonio, F. D., Giordano, S., & Tamagnone, L. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99257 · Cited by 78
Self-citationThe MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor
Coe, E. A., Tan, J. Y., Shapiro, M., Louphrasitthiphol, P., Bassett, A. R., Marques, A. C., Goding, C. R., & Vance, K. W. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008501 · Cited by 83
“Recent work has also reported that MITF-SOX10 drive the proliferative cell state in melanoma and influence the response to MAPKinase inhibiting therapeutics [30, 31].”
BackgroundCritical parameters in targeted drug development: the pharmacological audit trail
Banerji, U., & Workman, P. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.06.001 · Cited by 75
“analysis of the data and understanding the mechanisms of resistance, methods of clinic in melanomas can follow treatment with BRAF and MEK inhibitors; this could theoretically be circumvented by re-introducing the drug after a ‘drug holiday’ [106].”
MethodComputational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 86
“Nevertheless, not all patients have actionable alterations and those who do often have disease relapse and/or develop treatment resistance 1 .”
Kim, H., Frederick, D. T., Levesque, M. P., Cooper, Z. A., Feng, Y., Krepler, C., Brill, L. M., Samuels, Y., Hayward, N. K., Perlina, A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.049 · Cited by 79
“Notably, SOX10 depletion decreased RNF125 expression and increased EGFR transcript levels, consistent with our own results (Figure S4C) and independent studies (Sun et al., 2014).”
BackgroundResultInfluentialTargeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Smith, M. P., Rowling, E. J., Miskolczi, Z., Ferguson, J., Spoerri, L., Haass, N. K., Sloss, O., McEntegart, S., Arozarena, I., von Kriegsheim, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607156 · Cited by 77
“Amongst these was EGF, which together with its receptor has been previously implicated in BRAF inhibitor resistance through reactivation of ERK (Girotti et al, 2013; Sun et al, 2014).”
Whittaker, S. R., Cowley, G. S., Wagner, S., Luo, F., Root, D. E., & Garraway, L. A. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0136-t · Cited by 75
“EGFR (WIDR, SW1417 and LOXIMVI cells) (4, 22, 38) and MET (RKO”
BackgroundLorenzi, T., Chisholm, R. H., & Clairambault, J. (2016) · Biology Direct · doi:10.1186/s13062-016-0143-4 · Cited by 87
“[62], our model suggests that cancer cell populations may regain sensitivity to cytotoxic drugs after a ‘drug holiday’.”
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
Titz, B., Lomova, A., Le, A., Hugo, W., Kong, X., ten Hoeve, J., Friedman, M., Shi, H., Moriceau, G., Song, C., et al. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.28 · Cited by 72
The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma
Ahn, A., Chatterjee, A., & Eccles, M. R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0535 · Cited by 81
“Expression and activation of AXL, as determined by phosphorylation, as well as other RTKs was further increased upon exposure to vemurafenib.”
BackgroundInfluentialThe multifaceted anti-cancer effects of BRAF-inhibitors
Croce, L., Coperchini, F., Magri, F., Chiovato, L., & Rotondi, M. (2019) · Oncotarget · doi:10.18632/oncotarget.27304 · Cited by 84
“These include EGFR and platelet-derived growth factor receptor-β overexpressin [82], increased expression of the gene encoding the COT kinase [83], mutation of downstream MEK1 kinase [84], NRAS mutations [85], increased expression of tyrosine kinases receptor and amplification or alternative splicing of the BRAF gene…”
BackgroundFibroblast Growth Factor Receptor Signaling in Skin Cancers
Czyż, M. (2019) · Cells · doi:10.3390/cells8060540 · Cited by 79
“In drug-naïve BRAFV600 melanoma cells, the RTK expression is low, probably because the strong endogenous BRAF/NRAS mutation-driven activation of the MAPK-ERK signaling pathway selects, against cells with active RTK signaling, to prevent senescence [125].”
BackgroundTargeting EGFR in melanoma – The sea of possibilities to overcome drug resistance
Pastwińska, J., Karaś, K., Karwaciak, I., & Ratajewski, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188754 · Cited by 86
Distinct histone modifications denote early stress-induced drug tolerance in cancer
Emran, A. A., Marzese, D. M., Menon, D. R., Stark, M. S., Torrano, J., Hammerlindl, H., Zhang, G., Brafford, P. A., Salomon, M. P., Nelson, N. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23654 · Cited by 75
“A previous study denotes that drug holidayinduced sensitivity towards the same therapy is due to an oncogene-induced senescence-like state by supraphysiological levels of BRAF-MEK-ERK1/2 signalling in melanoma [31].”
BackgroundHDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy
Emmons, M. F., Faião-Flores, F., Sharma, R., Thapa, R., Messina, J. L., Becker, J. C., Schadendorf, D., Seto, E., Sondak, V. K., Koomen, J. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0040 · Cited by 73
“Cells were treated with 100 nM of Panobinostat or DMSO vehicle control (VC) for 24 hours and probed for phospho-EphA2, EphA2, phospho-AKT and AKT by Western Blot.”
InfluentialAdaptive stress signaling in targeted cancer therapy resistance
Pazarentzos, E., & Bivona, T. G. (2015) · Oncogene · doi:10.1038/onc.2015.26 · Cited by 69
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer
Mo, X., Niu, Q., Ivanov, A. A., Tsang, Y. H., Tang, C., Shu, C., Li, Q., Qian, K., Wahafu, A., Doyle, S. P., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.014 · Cited by 77
Schlegel, N. C., von Planta, A., Widmer, D. S., Dummer, R., & Christofori, G. (2015) · Experimental Dermatology · doi:10.1111/exd.12580 · Cited by 72
Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
Gnoni, A., Licchetta, A., Memeo, R., Argentiero, A., Solimando, A. G., Longo, V., Delcuratolo, S., & Brunetti, O. (2019) · Medicina · doi:10.3390/medicina55120754 · Cited by 74
“Nonetheless, novel insights suggested significant investigation in solid and hematological malignancies, with initial with promising results [42,43].”
BackgroundGirard, C. A., Lecacheur, M., Ben Jouira, R., Berestjuk, I., Diazzi, S., Prod'homme, V., Mallavialle, A., Larbret, F., Gesson, M., Schaub, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2914 · Cited by 70
“Differential gene expression was also examined in datasets derived from tumor biopsies from melanoma patients before and after development of drug resistance to BRAFi, MEKi, or BRAFi/MEKi combination [GSE50535 (25); Tirosh and colleagues (15)].”
BackgroundTargeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
Carlino, M. S., Long, G. V., Kefford, R. F., & Rizos, H. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.021 · Cited by 75
Rathod, D., Fu, Y., & Patel, K. R. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105039 · Cited by 78
Tian, Y., & Guo, W. (2020) · Medical Science Monitor · doi:10.12659/msm.920957 · Cited by 78
“Also, a study has shown that the inhibition of SOX10 induced the activation of TGF-b, resulting in the upregulation of EGFR and PDGFRb, which drove acquired resistance to MAPK inhibition in melanoma [66].”
BackgroundInfluentialSweetlove, M., Wrightson, E., Kolekar, S., Rewcastle, G. W., Baguley, B. C., Shepherd, P. R., & Jamieson, S. M. F. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00135 · Cited by 85
“These results were largely expected since loss of functional PTEN (16), EGFR upregulation (46) and high basal expression of pAKT (18–20) have been implicated in resistance to BRAF and MEK inhibition.”
BackgroundGenetic screening for single-cell variability modulators driving therapy resistance
Torre, E. A., Arai, E., Bayatpour, S., Jiang, C., Beck, L. E., Emert, B. L., Shaffer, S. M., Mellis, I. A., Fane, M. E., Alicea, G. M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00749-z · Cited by 75
Catalanotti, F., Cheng, D. T., Shoushtari, A. N., Johnson, D. B., Panageas, K. S., Momtaz, P., Higham, C., Won, H. H., Harding, J. J., Merghoub, T., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00054 · Cited by 62
“Median age, years (range) 56 (23-83) 49 (21-62) 54 (21-83) Stage at treatment, IIIC 1 1 2 IVA 4 2 6”
Martin, C. A., Cullinane, C. M., Kirby, L., AbuHammad, S., Lelliott, E. J., Waldeck, K., Young, R. J., Brajanovski, N., Cameron, D. P., Walker, R., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31220 · Cited by 74
BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity
Cabanillas, M. E., Patel, A. P., Danysh, B. P., Dadu, R., Kopetz, S., & Falchook, G. S. (2014) · Hormones and Cancer · doi:10.1007/s12672-014-0207-9 · Cited by 73
“These events may involve the activation of RTKs, such as ERBB family members and PDGFRβ, as they have been described to participate in the development of r e s i s t ance t o BRAF V600E k ina s e i nh ib i t i on [59,60,62,127,128].”
BackgroundMehnert, J. M., Mitchell, T. C., Huang, A. C. C., Alemán, T. S., Kim, B. J., Schuchter, L. M., Linette, G. P., Karakousis, G. C., Mitnick, S., Giles, L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3382 · Cited by 70
“In patients with elevated serum LDH, there was increased expression of many regulators previously linked to BRAF inhibitor resistance including VEGF (28), EGF (29), ERBB2 (30), HGF (31), FOS (32), and ERK (9).”
BackgroundUnderstanding the role of phenotypic switching in cancer drug resistance
Gunnarsson, E. B., De, S., Leder, K., & Foo, J. (2020) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2020.110162 · Cited by 79
“[24, 25, 26, 27, 28], as well as recent reviews by Reyes and Lahav [29] and Salgia and Kulkarni [30].”
ResultKohlhapp, F. J., Broucek, J. R., Hughes, T. M., Huelsmann, E. J., Lusciks, J., Zayas, J. P., Dolubizno, H., Fleetwood, V. A., Grin, A., Hill, G. R., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0063-3 · Cited by 69
“The benefits in survival are complicated by a nearly universal emergence of drug resistance and tumor recurrence [6].”
BackgroundWang, H., Sheehan, R. P., Palmer, A. C., Everley, R. A., Boswell, S. A., Ron‐Harel, N., Ringel, A. E., Holton, K. M., Jacobson, C. A., Erickson, A. R., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.03.009 · Cited by 71
“Adaptive responses often result in drug tolerance (Sun et al., 2014) but whether this occurs in CMs is unknown.”
BackgroundDeciphering mechanisms of brain metastasis in melanoma - the gist of the matter
Redmer, T. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0854-5 · Cited by 67
“This is marked by an up-regulation of receptor tyrosine kinase receptors PDGFRB [142] or EGFR [143], signaling mediators such as CRAF or NRAS, and the acquisition of mutations in MEK1, MEK2 and NRAS that trigger a stimulation of the RAS/RAF/MAPK pathway (reviewed in [144]).”
BackgroundMechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Satoh, Y., Ishii, N., & Aoki, M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0927-t · Cited by 69
Hendricks, W. P. D., Zismann, V., Sivaprakasam, K., Legendre, C., Poorman, K. A., Tembe, W., Perdigones, N., Kiefer, J., Liang, W. S., DeLuca, V. J., et al. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007589 · Cited by 73
Wang, B., Zhang, W., Zhang, G., Kwong, L., Lu, H., Tan, J., Sadek, N., Xiao, M., Zhang, J., Labrie, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01911-5 · Cited by 66
Metadata
- Authors
- Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F. A., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. M., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Institut Gustave Roussy (FR)
- Candiolo Cancer Institute (IT)
- IFOM (IT)
- ORCID
- Sun, Chong
- Wang, Liqin
- Huang, Sidong
- Heynen, Guus J. J. E.
- Prahallad, Anirudh
- Robert, Caroline
- Haanen, John
- Blank, Christian
- Wesseling, Jelle
- Willems, Stefan M.
- Zecchin, Davide
- Lieftink, Cor
- Hofland, Ingrid
- Schlicker, Andreas
- Wessels, Lodewyk F. A.
- Beijersbergen, Roderick L.
- Bardelli, Alberto
- Eggermont, Alexander M. M.
- Venue
- Nature
- Published
- 2014-03-26
- Volume
- 508
- Issue
- 7494
- Pages
- 118-122
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985928174
- Cited by
- 888
- References
- 30
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 62 · 2023: 58 · 2022: 90 · 2021: 81 · 2020: 71 · 2019: 76 · 2018: 75 · 2017: 83 · 2016: 71 · 2015: 107 · 2014: 39
- FWCI
- 40.97
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP130540)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- BRAF inhibitor resistance, SOX10, TGF-beta signaling, PDGFRβ, oncogene-induced senescence, drug holidays, MEK inhibitors, adaptive resistance, shRNA screen, cell proliferation, tumor heterogeneity, drug re-sensitization, receptor tyrosine kinase
- MeSH terms
- Vemurafenib, Animals, Antineoplastic Agents, Female, Flow Cytometry, Humans, Indoles, Melanoma, Sulfonamides, Signal Transduction, Gene Library, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Cellular Senescence, Drug Resistance, Neoplasm, Receptor Protein-Tyrosine Kinases, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinase Kinases, RNA, Small Interfering, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, SOXE Transcription Factors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.